Study suggests glucagon-like peptide-1 receptor agonists related to adolescent weight loss

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics.

GLP-1 receptor agonist therapy, approved for adults with , reduces body weight by enhancing satiety and suppressing appetite, even in patients without diabetes, according to the study background.

Aaron S. Kelly, Ph.D., of the University of Minnesota Medical School, Minneapolis, and colleagues conducted a three-month, placebo-controlled trial followed by a three-month open-label extension during which medication was offered to all patients. A total of 22 patients (12 to 19 years of age) completed the trial, in which the medication exenatide was administered subcutaneously (injected).

"The results of this clinical trial extend the findings of our previous pilot and feasibility study and offer additional evidence, within the context of a randomized, placebo-, that treatment with a GLP-1 receptor agonist significantly reduces BMI and body weight in adolescents with severe obesity," the authors note.

Exenatide caused a greater reduction in BMI compared with placebo (-2.7 percent). Researchers also observed a further reduction in BMI during the open-label phase for those patients initially randomized to exenatide (cumulative BMI reduction of 4 percent). The medication also resulted in a reduction, on average, in systolic blood pressure of -6mm HG, although researchers note it did not reach the level of statistical significance.

"In conclusion, data from the current study provide evidence that GLP-1 receptor agonist treatment reduces BMI and elicits a potentially meaningful reduction in SBP in adolescents with severe obesity," the authors conclude.

More information: JAMA Pediatr. Published online February 4, 2013. doi:10.1001/jamapediatrics.2013.1045

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

PCV13 recommended for 6- to 18-year-olds at high risk

9 hours ago

(HealthDay)—Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according to a policy ...

Brain abnormality found in group of SIDS cases

Nov 25, 2014

More than 40 percent of infants in a group who died of sudden infant death syndrome (SIDS) were found to have an abnormality in a key part of the brain, researchers report. The abnormality affects the hippocampus, ...

Eczema cases rising among US children

Nov 24, 2014

(HealthDay)—A growing number of children are being diagnosed with the allergic skin condition eczema—but it can usually be eased with topical treatments, according to a new report.

Adult-sized ATVs deadly for kids, report shows

Nov 24, 2014

(HealthDay)—Santa might think twice about giving kids an all-terrain vehicle this year. Riding ATVs poses high risks of injury or death for children and teens, with dangers differing by age, a new U.S. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.